Reprogrammed lipid metabolism in bladder cancer with cisplatin resistance

Min Young Lee; Austin Yeon; Muhammad Shahid; Eunho Cho; Vikram Sairam; Robert Figlin; Khae-Hwan Kim; Jayoung Kim

doi:10.18632/oncotarget.24229

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Research Papers:

Reprogrammed lipid metabolism in bladder cancer with cisplatin resistance

Min Young Lee, Austin Yeon, Muhammad Shahid, Eunho Cho, Vikram Sairam, Robert Figlin, Khae-Hwan Kim and Jayoung Kim _

PDF | HTML | Supplementary Files | How to cite

Oncotarget. 2018; 9:13231-13243. https://doi.org/10.18632/oncotarget.24229

Metrics: PDF 1957 views | HTML 3022 views | ?

Abstract

Min Young Lee1, Austin Yeon2, Muhammad Shahid2, Eunho Cho3, Vikram Sairam3, Robert Figlin4, Khae-Hwan Kim5 and Jayoung Kim2,3,4,5

1Institute for Systems Biology, Seattle, WA, USA

2Department of Surgery and Biomedical Sciences, Cedars-Sinai Medical Center, Los Angeles, CA, USA

3University of California Los Angeles, Los Angeles, CA, USA

4Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA, USA

5Department of Urology, Ga Cheon University College of Medicine, Incheon, South Korea

Correspondence to:

Jayoung Kim, email: [email protected]

Khae-Hwan Kim, email: [email protected]

Keywords: lipidomics; cisplatin resistance; bladder cancer

Received: October 06, 2017 Accepted: January 06, 2018 Published: January 13, 2018

ABSTRACT

Due to its tendency to recur and acquire chemoresistance quickly, bladder cancer (BC) remains to be an elusive and difficult disease. Patients with recurrent and chemoresistant BC have an extremely poor prognosis. One possible approach that may provide insightful and valuable information regarding resistance mechanisms is looking into the lipid metabolism of BC cells. Metabolism of lipids is essential for cancer cells and is associated with the regulation of a variety of key cellular processes and functions. This study conducted a comparative lipidomic profiling of two isogenic human T24 bladder cancer cell lines, one of which is clinically characterized as cisplatin-sensitive (T24S) and the other as cisplatin-resistant (T24R). Immunohistochemistry analysis revealed that expression of cytosolic acetyl-CoA synthetase 2 (ACSS2) is positively correlated with aggressive BC. Ultra performance liquid chromatography-mass spectrometry (UPLC-MS) analysis profiled a total of 1,864 lipids and levels of differentially expressed lipids suspected of being associated with cisplatin resistance were determined. In addition, we found that ACSS2 inhibition greatly perturbed levels of metabolites, including CE(18:1), CE(22:6), TG(49:1), and TG(53:2). This study broadens our current knowledge on the links between cisplatin resistance and lipid metabolism in aggressive BC and suggests potential biomarkers for identifying higher-risk patients.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 24229

Publication Alerts

Research Papers:

Reprogrammed lipid metabolism in bladder cancer with cisplatin resistance

Abstract